FDA Expert Panel Shoots Down Chronic Kidney Disease Drug

An FDA advisory committee unanimously rejected recommending approval of Reata Pharmaceuticals’ bardoxolone methyl as a treatment for patients 12 years and up with chronic kidney disease caused by Alport syndrome (AS), a rare genetic disorder.
Source: Drug Industry Daily